BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Development Business,	1.13M	72.00K	354.00M	529.00M
Pharmaceutical Development Business, Growth	1473.61%	-99.98%	-33.08%	-
Total	1.13M	72.00K	354.00M	529.00M
Total Growth	1473.61%	-99.98%	-33.08%	-

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2018	Mar 31, 2017
Japan	1.13M	72.00K	354.00M	529.00M
Japan Growth	1473.61%	-99.98%	-33.08%	-
Total	1.13M	72.00K	354.00M	529.00M
Total Growth	1473.61%	-99.98%	-33.08%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 16, 2026

Data Sources Report a data error